Paid Clinical Trials Ann Arbor

Discover 1,904 paid clinical trials in Ann Arbor, Michigan. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,904

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionA Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Recruiting

PHASE1

PHASE2

Sponsor:

Amgen

Location:

Detroit MI, Indianapolis IN, Toronto, Nashville TNshow 9 more

Code:

NCT05325866

Conditions

Solid Tumors

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Bemarituzumab

A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

Recruiting

PHASE2

PHASE3

Sponsor:

Cytokinetics

Location:

Ann Arbor MI, Detroit MI, Chicago IL, Milwaukee WIshow 18 more

Code:

NCT06412666

Conditions

Pediatric

Symptomatic Obstructive Hypertrophic Cardiomyopathy

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Aficamten

Placebo

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative ColitisA Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Recruiting

PHASE2

Sponsor:

Pfizer

Location:

Royal Oak MI, Cleveland OH, Chicago IL, Rochester NYshow 14 more

Code:

NCT05287126

Conditions

Ulcerative Colitis

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Etrasimod

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid TumorsA Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors

Recruiting

PHASE1

PHASE2

Sponsor:

Marengo Therapeutics, Inc.

Location:

Detroit MI, Columbus OH, Toronto, Bethesda MDshow 4 more

Code:

NCT05592626

Conditions

Advanced Solid Tumors

Genital Neoplasm, Female

Urogenital Neoplasms

Lung Neoplasm

Neoplasms by Site

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

STAR0602

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

Recruiting

PHASE3

Sponsor:

VistaGen Therapeutics, Inc.

Location:

Bloomfield Township MI, Chicago IL, Cincinnati OH, Naperville ILshow 12 more

Code:

NCT06615557

Conditions

Social Anxiety Disorder (SAD)

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Fasedienol Nasal Spray

Placebo Nasal Spray

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABGAnticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Recruiting

PHASE3

Sponsor:

Icahn School of Medicine at Mount Sinai

Location:

Ann Arbor MI, Fort Wayne IN, Cleveland OH, Londonshow 45 more

Code:

NCT04045665

Conditions

Atrial Fibrillation

Stroke

Bleeding

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Antiplatelet-only strategy

Oral Anticoagulant plus background antiplatelet therapy

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Southfield MI, Fort Wayne IN, Lima OH, Middleburg Heights OHshow 172 more

Code:

NCT05026866

Conditions

Alzheimer Disease

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Not accepted

Interventions

Donanemab

Placebo

HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and BortezomibHLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

Recruiting

PHASE2

Sponsor:

Henry Ford Health System

Location:

Detroit MI

Code:

NCT03850366

Conditions

Hematological Malignancy

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Bortezomib

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Recruiting

PHASE2

Sponsor:

Genentech, Inc.

Location:

Detroit MI, Chicago IL, Indianapolis IN, Cincinnati OHshow 22 more

Code:

NCT05968326

Conditions

Adenocarcinoma, Pancreatic Ductal

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Autogene cevumeran

Atezolizumab

mFOLFIRINOX

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Ann Arbor MI, Ypsilanti MI, Canton MI, Chelsea MIshow 706 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression